Changes in Serum Metabolome Following Low-Energy Diet-Induced Weight Loss in Women with Overweight and Prediabetes: A PREVIEW-New Zealand Sub-Study.

As obesity develops, metabolic changes increase the risk of non-communicable diseases such as type 2 diabetes (T2D). Weight loss is crucial for improving health in T2D and cardiometabolic conditions. However, weight loss rates vary between individuals, even with identical diets or energy restrictions, highlighting the need to identify markers or predictors of weight loss success to enhance intervention outcomes.

A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.

Purpose: Regorafenib is a novel oral multikinase inhibitor of angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and oncogenic kinases (KIT, RET, and RAF). This first-in-man, phase I dose-escalation study assessed the safety, pharmacokinetic, pharmacodynamic, and efficacy profiles of regorafenib in patients with advanced solid tumors.

Patients And Methods: Patients aged 18 years or older with advanced solid tumors refractory to standard treatment were recruited.

Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer.

Background: Telatinib (BAY 57-9352) is an orally available, small-molecule inhibitor of vascular endothelial growth factor receptors 2 and 3 (VEGFR-2/-3) and platelet-derived growth factor receptor β tyrosine kinases.

Methods: In this multicenter phase I dose-escalation study including a phase II like expansion part, 39 patients with refractory colorectal cancer (CRC) were enrolled into 14 days on / 7 days off in repeating cycles of 28 days (n = 11) or continuous dosing groups (n = 28) to receive ≥ 600 mg telatinib twice-daily (bid).

Results: Hypertension (28%) and diarrhoea (15%) were the most frequent study drug-related adverse events of CTC grade 3.

Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis.

Background: EndoTAG-1 (ET), a novel formulation of cationic liposomes carrying embedded paclitaxel (Taxol), shows antitumoral activity, targeting tumor endothelial cells in solid tumors. Patients with advanced metastatic cancer were evaluated investigating effects on pharmacokinetics and tumor vasculature using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and contrast-enhanced ultrasound (CEUS).

Patients And Methods: The pharmacokinetic (PK) profile of ET (22 mg/m(2) i.

DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study.

Background: Vandetanib is a once-daily oral inhibitor of VEGFR, EGFR and RET signaling pathways. In patients with advanced colorectal cancer and liver metastases, the effect of vandetanib on tumor vasculature was assessed using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).

Methods: Eligible patients received vandetanib 100 or 300 mg/day.

Onset and maintenance of angiogenesis in biomaterials: in vivo assessment by dynamic contrast-enhanced MRI.

Objective: To describe dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as a practical tool for longitudinal assessment of angiogenesis in biomaterials.

Background: There is a lack of suitable methods for in vivo evaluation of the integration of biomaterials in a clinical setting. In oncology, DCE-MRI is used for the longitudinal monitoring of altered tumor angiogenesis during therapy.

[Oxygen-enhanced MRI of the lung: optimized calculation of difference images].

Background: In oxygen-enhanced lung MRI, difference maps of acquisitions during inhalation of room air and pure oxygen are calculated to assess lung function. The purpose of this study was to analyze how the calculation of these difference maps depends on the delayed signal change after switching the gas supply.

Methods: Ten healthy volunteers were examined with an ECG and respiratory-triggered T1-weighting inversion recovery HASTE sequence with parallel imaging.

Fast oxygen-enhanced multislice imaging of the lung using parallel acquisition techniques.

The purpose of this study was to evaluate an optimized multislice acquisition technique for oxygen-enhanced MRI of the lung using slice-selective inversion and refocusing pulses in combination with parallel imaging. An inversion recovery HASTE sequence was implemented with respiratory triggering to perform imaging in end-expiration and with ECG triggering to avoid image acquisition during the systolic phase. Inversion pulses and the readout of echo trains could be interleaved to decrease acquisition time.